 - To assess the response partial and complete response in patients with relapsed or refractory multiple myeloma receiving bortezomib, doxorubicin hydrochloride, and dexamethasone PAD after prior treatment with a maximum of 6 courses of vincristine, doxorubicin, and dexamethasone VAD or VAD-like regimen. 